Literature DB >> 10717629

Prostate carcinoma trends in three counties in Sweden 1987-1996: results from a population-based national cancer register. South-East Region Prostate Cancer Group.

G Sandblom1, M Dufmats, K Nordenskjöld, E Varenhorst.   

Abstract

BACKGROUND: To detect changes in the incidence rate and management of prostate carcinoma, all cases of the disease diagnosed in the southeast region of Sweden between 1987-1996 were recorded.
METHODS: The register is based on Swedish personal registration numbers, thereby minimizing the number of dropouts. All cases of prostate carcinoma detected in the southeast region have been recorded according to a defined protocol that has been updated successively to match recent views regarding the disease. To ensure a high number of presented cases, the National Cancer Register was checked for missing cases.
RESULTS: Six thousand seven hundred eighty-two cases of prostate carcinoma were registered in the region between 1987-1996. The age-adjusted incidence rate reached a peak in 1993, followed by a slight decrease. The mean age at diagnosis throughout the period was 74.2 years, with a peak age of 74.8 years in 1992. The number of incidental tumors followed the development of the number of transurethral resections of the prostate performed in the region, with a peak in 1991. The percentage of patients receiving gonadotropin-releasing hormone (GnRH) analogues increased from 3.9% to 37.8% whereas the percentage of patients treated with orchiectomy decreased from 40.0% to 12.8% and the percentage of those treated with radical prostatectomy decreased from 11.1% to 2.5%.
CONCLUSIONS: A diminishing pool of latent tumors may explain the decreasing incidence rate and lower age at diagnosis observed after 1993. Orchiectomy is rapidly being superseded by GnRH analogues. In contrast to trends reported in the U.S., the percentage of men with prostate carcinoma undergoing total prostatectomy appears to be declining in Sweden. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10717629     DOI: 10.1002/(sici)1097-0142(20000315)88:6<1445::aid-cncr24>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker.

Authors:  Geng Zhang; Hongtao Zhang; Qiang Wang; Priti Lal; Ann M Carroll; Margarita de la Llera-Moya; Xiaowei Xu; Mark I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-18       Impact factor: 11.205

2.  Prostate cancer incidence and mortality rates and trends in the United States and Canada.

Authors:  Kathleen McDavid; Judy Lee; John P Fulton; Jon Tonita; Trevor D Thompson
Journal:  Public Health Rep       Date:  2004 Mar-Apr       Impact factor: 2.792

3.  Temporal trends in cause of death among Swedish and US men with prostate cancer.

Authors:  Mara M Epstein; Gustaf Edgren; Jennifer R Rider; Lorelei A Mucci; Hans-Olov Adami
Journal:  J Natl Cancer Inst       Date:  2012-07-25       Impact factor: 13.506

4.  Pain and health-related quality of life in a geographically defined population of men with prostate cancer.

Authors:  G Sandblom; P Carlsson; P Sigsjö; E Varenhorst
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

5.  A population-based study of pain and quality of life during the year before death in men with prostate cancer.

Authors:  G Sandblom; P Carlsson; K Sennfält; E Varenhorst
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.